New Imaging Links Whole-Body Cancer Scans to Single Cells

Imagine following a single cancer cell from a distant organ to its microscopic neighborhood. That is exactly what a new imaging approach developed in Scotland makes possible — a kind of molecular road trip that starts with a whole-body scan and ends at the doorstep of an individual tumor cell.

Traditional medical imaging and microscopy have long felt like two separate worlds. PET scans and whole-body imaging show where disease is lurking, but they blur the tiny details. Microscopes expose those details, yet they cannot tell you how a lesion sits within the living body. The Scottish team has bridged that gap by combining PET with bioluminescence and fluorescence so researchers can find the tumors that matter and then examine the same spots at cellular resolution.

It sounds simple. It is not. Cells must be labeled so they remain visible across imaging methods. Signals have to be registered between machines with wildly different scales. The payoff, however, is immediate: scientists can now trace how specific cancer cell populations move, multiply, and react to treatment, while also seeing how the local environment — immune cells, blood vessels, stromal tissue — shapes that behavior.

Professor David Lewis and colleagues at the Cancer Research UK Scotland Institute and the University of Glasgow led the work. Their method is preclinical, demonstrated in mouse models of liver and lung tumours, but it already rewrites how experiments can be designed. Instead of treating every lesion as the same, researchers can pick out the most relevant lesions in a living animal and follow them through time, then peel back layers down to the single-cell level.

Why does that matter? Because cancer is not uniform. Even within the same patient, separate tumours can evolve different strategies — some respond to therapy, others shrug it off. By linking macro-scale imaging with micro-scale biology, this technique helps reveal the hidden differences that influence growth, spread, and drug resistance. It gives context to cellular snapshots.

This is not just about oncology. The underlying idea — connect broad, noninvasive scans with high-resolution tissue analysis — could reshape preclinical research in immunology, neuroscience, and regenerative medicine. When you can tag and trace particular cells across imaging platforms, questions that once seemed abstract become testable. Which immune cells infiltrate a lesion? How do blood vessels remodel around growing tumours? Which clones seed metastases?

The public health stakes are clear. More than 403,000 people in the UK receive a cancer diagnosis each year, including roughly 34,800 in Scotland. About 170,000 deaths follow annually nationwide, with around 16,400 in Scotland. Better models and imaging tools help researchers zero in on why treatments fail in some lesions and succeed in others, potentially steering therapies toward more precise, lesion-specific strategies.

At the moment, the approach is a research tool, not a clinical scanner. That distinction matters. Mice and human bodies are not interchangeable, but preclinical systems like this one accelerate discovery. They let teams test hypotheses about tumour biology and therapy response with a level of spatial and temporal control that was previously out of reach.

By marrying whole-body views with single-cell detail, scientists gain a new compass for navigating cancer's complexity.

It is a small revolution in imaging, quiet but practical: a way to decide which tumours to follow, how to study them, and ultimately how to design smarter treatments. The next step is obvious — refine the tools, validate findings across more models, and see which insights survive the leap toward human studies — and when that happens, the map of cancer will look more detailed than ever before.